Policy expert pushes for ban on off-label prescribing of psychoactive drugs

07/5/2011 | Forbes

Cases of drugmakers' settling off-label marketing cases has prompted calls to prohibit prescribing of psychoactive drugs for nonindicated uses. A rise in diagnoses of certain mental disorders, especially in children, has paralleled a philosophical shift from psychotherapy to medication and reflects doctors', drugmakers' and some Medicaid recipients' financial stakes in psychoactive drugs, says Marcia Angell, a senior lecturer in social medicine at Harvard Medical School and former editor-in-chief of the New England Journal of Medicine.

View Full Article in:

Forbes

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Corporate Counsel - Regulatory Law
Regeneron
Tarrytown, NY
Program Coordinator/Lecturer for the Regulatory Science program
Johns Hopkins University
Washington, DC
Senior Attorney
Blue Cross Blue Shield of Louisiana
Baton Rouge, LA
Senior or Principal Consultant
PAREXEL International
Nationwide, SL_Nationwide
Chief Financial Officer
Health Alliance Plan of Michigan
Southfield, MI